Oncotarget is a medical journal that publishes papers on oncology and is released weekly. The journal is open-access. It is free for all and anyone is allowed to view it. It is also a peer-reviewed journal which means that research must be reviewed and counter-checked by other members of the scientific community before Oncotarget publishes it.
The editors-in-chief at Oncotarget are Mikhail Blagosklonny and Andrei Gudkov, both of whom work at the Roswell Park Cancer Institute in New York. Blagosklonny is a professor of oncology at the Institute. He is an expert in fields such as cancer and aging. Gudkov is a senior vice president for basic research at the Institute and a professor of cell stress biology.
Research Gate has it that its editorial board is made up of distinguished scientists and researchers including some who have won Lasker Awards. They are the reason why Oncotarget is where it is today because they ensure that the quality is very high.
Oncotarget is indexed by BIOSIS Previews, PubMed, and Scopus where they have been ranked Q1 for five years in a row. The journal was started in 2010 and has become the top journal covering research on oncology. Oncotarget is published by Impact Journals and archives of previous issues can be found on the journal’s site.
The journal has turned out to be successful. It has maintained an impact factor of 5.00 since its founding. The editors saw it best to include other sections that are closely related with oncology including cardiology, aging, neuroscience, and immunology even though it started by focusing on one field only.
According to Dove Press, Oncotarget has made it easier for scientific research to spread faster because it is published online instead of being printed and distributed. Discoveries are shared quickly, and this is a huge advantage for the scientists and researchers who would like many people to know about their scientific breakthroughs.
Oncotarget has facilitated the collaboration of scientists from different fields which has led to significant discoveries. Oncotarget has published some of the most important papers of recent years because of the relationship that it maintains with the researchers.